

Valuing the patient experience in HTAs (and healthcare delivery assessments): going beyond QALYs

Professor Mandy Ryan

Health Economics Research Unit, University of Aberdeen

HERU is supported by the Chief Scientist Office of the Scottish Government Health Directorates and the University of Aberdeen. The author accepts full responsibility for this talk.

Structure

- Background valuation in (health) economics
- Valuing the Patient Experience Project
 - > The importance of going beyond QALYs
 - Valuation methods for going beyond QALYs
 - Group Work
- Concluding thoughts/reflections.... And discussion...

Background

- Limited resources opportunity cost!
- Costs and benefits must be compared
- Valuing Benefit (estimating a quantifiable estimate of worth (QEW)) - one of greatest challenges facing economists

Valuation in Health Economics

• Pre 1970 - cost-benefit analysis (CBA)

➢ willingness to pay (WTP) − through contingent valuation

• 1970s - cost-effectiveness analysis (CEA)

e.g. cost per life year

• <u>1980s - cost-utility analysis (CUA)</u>

<u>e.g. cost per Quality Adjusted Life Years (QALYs) – HEALTH</u> <u>MAXIMISATION!</u>

<u>Standard gamble or time trade off</u>

• 1990s - <u>cost-benefit analysis (CBA)</u>

- Costs and benefits both measured in monetary terms
- health and patient experience factors
- Challenge of valuation
 - contingent valuation and discrete choice experiments (DCEs)

• 2000 forward

- > QALYs dominate at policy level (NICE, SMC)
- > valuing patient experience factors important



Quality Adjusted Life Years

Concerned with both quantity and quality of life

Increase in years of life = 10

Quality/utility weight = 0.85 scale 0-1, 0=dead; 1=perfect health

 $QALYs = 10 \ge 0.85 = 8.5$



QALY framework

• H(Q) is measured on a scale whereby death and full health are assigned values of 0 to 1 respectively

> Standard gamble – probability level of indifference


Time trade-off – trade time (years at end of life willing to give up)



Standard Gamble

- Individual chooses between a <u>certain outcome</u> (B) or a <u>gamble</u> which may result in either a better outcome (A) than B (with probability P) or a worse outcome (C) (with probability 1-p).
- P* = level at which indifferent between certain outcome and gamble
- P* = quality weight

Standard Gamble




Time trade off

- Individual is presented with a choice between living for a period t in a specified but less than perfect state (outcome B) versus having a healthier life (outcome A) for a time period h (where h<t).
- h varied until respondent indifferent between outcome A and B
- h/t = quality weight

Time trade off

Health State (H)



Valuation in Health Economics

• Pre 1970 - cost-benefit analysis (CBA)

➢ willingness to pay (WTP) − through contingent valuation

• 1970s - cost-effectiveness analysis (CEA)

➢ e.g. cost per life year

• 1980s - cost-utility analysis (CUA)

- e.g. cost per Quality Adjusted Life Years (QALYs) HEALTH MAXIMISATION!
 - Standard gamble or time trade off

• 1990s - <u>cost-benefit analysis (CBA)</u>

- Costs and benefits both measured in monetary terms
- health and patient experience factors
- Challenge of valuation
 - contingent valuation and discrete choice experiments (DCEs)
- 2000 forward
 - QALYs dominate at policy level (NICE, SMC)
 - valuing patient experience factors important



Valuation in Health Economics - House of commons health select committee review of NICE (January 2008)

Time consuming

Questions thresholds

• Empirical work looking at WTP for QALY

Criticises information used

'The law must be changed to allow NICE to take account of wider benefits to society.....'

Yet..... NICE recent guidance (June 2008)

- Cost-effectiveness (specifically cost-utility) analysis is the preferred form of economic evaluation..... Health effects should be expressed in terms of QALYs.
- The focus on cost-effectiveness analysis is justified by the more extensive use and publication of these methods compared with cost-benefit analysis and the focus of the Institute on maximising health gains....'

Valuation in Health Economics

• Pre 1970 - cost-benefit analysis (CBA)

➢ willingness to pay (WTP) − through contingent valuation

• 1970s - cost-effectiveness analysis (CEA)

e.g. cost per life year

• 1980s - cost-utility analysis (CUA)

- e.g. cost per Quality Adjusted Life Years (QALYs) HEALTH MAXIMISATION!
 - Standard gamble or time trade off

• 1990s - <u>cost-benefit analysis (CBA)</u>

- Costs and benefits both measured in monetary terms
- health and patient experience factors
- Challenge of valuation
 - contingent valuation and discrete choice experiments (DCEs)

• 2000 forward

- QALYs dominate at policy level (NICE, SMC)
- valuing patient experience factors important



UK MRC Methodology Panel (early 2008) -Valuing the Patient Experience

- Importance of patient experience factors
 - Quality outcome measures/frameworks in England/Wales and Scotland

Increasing literature in health services research (including health economics)

- National Institute for Health Research (NIHR) commissioned research:
 - > What is meant by patient experiences
 - > How to value patient experiences
 - We will come back to this...

Michael Parkinson, Ambassador for Government's Dignity in Care Campaign

- said there was a danger that carers did not see a "person who had lived a life, a worthwhile person, but a piece of decrepit and useless flesh".
 - Patients can't reach the food
 - > When they ring the bell to get help with going to the toilet they are left lying in their own urine

Mid Staffordshire NHS Trust...

• Routine neglect

Patients left in soiled sheets which relatives were forced to wash
Patients left alone, leading to falls (not reported)
Problems getting food and drink

Government Report: 'criticised the ineffective management which was too often concerned with hitting targets, particularly in A&E, as well as the lack of compassion and uncaring attitude of staff'

Patients' judgements on being ill and being rare (Huyard, 2009)

• 'The participants strongly expressed an aspiration to feel morally well-treated as a patient, which includes the feeling of being listened to, of being taken seriously, and of being supported and informed according to one's needs. In this regard, the disease experience presented here suggests that better fulfilling these expectations would greatly improve the subjective situation of patients with a rare disease.'

UK MRC Methodology Panel (early 2008) -Valuing the Patient Experience

- Importance of patient experience factors
 - Quality outcome measures/frameworks in England/Wales and Scotland
 - Increasing literature in health services research (including health economics)
- <u>National Institute for Health Research (NIHR)</u> <u>commissioned research:</u>
 - > What is meant by patient experiences
 - How to value patient experiences
 - We will come back to this...

'Valuing Patient Experiences' project









Background

- Project commissioned by National Institute Health Research (NIHR), UK
- Resource allocation decisions may not adequately reflect what matters to people about healthcare other than health
- Techniques for valuing aspects of healthcare experience (beyond health) not well developed

Project aims

• Stage 1:

- To identify and characterise the aspects of healthcare experience that matter to people
- To develop a 'conceptual map' to facilitate consideration/discussion of these
- Stage 2:
 - To review techniques for generating quantitative estimates of the worth (QEW) of the aspects of healthcare experience that matter















Stage 1: What aspects of healthcare experience matter to people, and why?











Two main activities:

'Bottom up'

• Review of studies of what matters about healthcare experience

'Top down'

• Look at 'frameworks' and theories that might help organise our thinking about what matters

'Bottom up' review



Possible organising frameworks?

• Healthcare quality


e.g. Institute of Medicine, WHO 'Responsiveness'

• Healthcare experience

e.g. Mike Nolan's 'Senses' framework

• 'Overall' wellbeing

e.g. Carol Ryff's 'Subjective wellbeing'



Healthcare enables me to live a good life, supporting my capabilities to flourish as a human being.

Ambition for conceptual map

- Aiming for broad relevance, but
- Recognising that 'what matters' can vary


(people have diverse health issues, social/cultural backgrounds, personal concerns and interests... and services have different aims and constraints)

A 'generic' starter map, that summarises aspects of experience that most people will recognise as important, that has with enough detail to be meaningful, but leaves scope for more detailed specification. Open for discussion and revision.

"Healthcare enables me to live a good life. supporting my capability to flourish as a human being"



Health care enables me to



Are just

patient

dedicated

Do not judge me inappropriately Do not treat me according to stereotype

Stage 2 - Generating Quantifiable Estimates of Worth for Patient Experiences

- Best Worst Scaling
- Conjoint Analysis ranking
- Conjoint Analysis rating
- Discrete choice experiments
- Willingness to pay/contingent valuation
- Person Trade-off
- Standard Gamble*
- Time Trade Off*
- * Used to estimate quality weights within QALY framework
- Budget Pie/Allocation of Points
- Swing weighting

Group Work

Your views on the acceptability of the different approaches identified for generating a quantifiable estimate of worth

Concluding thoughts

Incorporating patient experiences into the economic evaluationchallenges for valuation?

Incorporating patient experiences into the economic evaluation would it make a difference?